A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026.The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients.In a letter to Novo dated Feb. 5, the FDA said the ad misbrands the oral drug, making its distribution a violation of federal law. The agency requested that the drugmaker take immediate action to address the v ...

Group 1 - The FDA has deemed a television advertisement for Novo Nordisk's weight loss pill as "false or misleading" [1] - The communication from the FDA was documented in a letter dated February 5 [1]

The US Food and Drug Administration said a TV advertisement for Novo Nordisk’s new weight-loss pill included “false or misleading” claims about the drug’s ability to help users shed pounds, adding to the drugmakers’ recent woes https://t.co/R2YYXWdMR2 ...

Core Insights - Pfizer's fourth-quarter results exceeded earnings and sales estimates, but total revenues declined by 3% operationally due to a 40% drop in COVID-19 product revenues [2][10] - The company reaffirmed its 2026 outlook, which anticipates lower revenues and earnings per share due to the decline in COVID product sales and upcoming patent expirations [12][13] Financial Performance - Pfizer reported a 5% year-over-year increase in earnings, despite a significant decline in revenues from COVID-19 products [2] - Total revenues for 2026 are projected to be between $59.5 billion and $62.5 billion, down from $62.6 billion in 2025 [12] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80 to $3.00, a decrease from $3.22 in 2025 [13] Product Portfolio and Pipeline - Pfizer's oncology segment, which accounts for approximately 27% of total revenues, saw an 8% revenue growth in 2025, driven by key drugs [7] - The company is expanding its obesity portfolio with the acquisition of Metsera, which added a new investigational drug, PF'3944, showing promising results in a phase IIb study [3][9] - Revenues from non-COVID products increased by 6% operationally in 2025, with recently launched and acquired products generating $10.2 billion [8] Market Challenges - Sales of COVID products, Comirnaty and Paxlovid, have significantly declined, with projections of around $5 billion in 2026, down from $6.7 billion in 2025 [15][14] - Pfizer anticipates a revenue impact of approximately $1.5 billion due to loss of exclusivity for several key products between 2026 and 2030 [16] - The redesign of Medicare Part D under the Inflation Reduction Act is expected to continue negatively affecting revenues in 2026 [17] Stock Performance and Valuation - Pfizer's stock has underperformed compared to the industry and the S&P 500, with a 5.2% increase over the past year [18] - The stock is currently trading at a price/earnings ratio of 9.20, below the industry average of 18.76 and its five-year mean of 10.24 [21] - Analysts have revised the consensus estimate for 2026 earnings down from $2.99 to $2.98 per share over the past month [24]

Well, as you highlighted, HIMS cratering while Novo shares pop. The pharma giant filing a lawsuit this morning against the tellahalth company, asking the court to permanently ban HIMS from selling all compounded versions of its drugs, citing patent infringement. The FDA, which referred HIMS to the DOJ on Friday, also threatened legal action.Now, in response over the weekend, HIMS said they would pull their GLP-1 oral medicine that they announced only a few days prior. Novo in the complaint saying, "Other ph ...

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Let's talk all things public health this morning, including the fight between Novo Nordisk and hims and hers over GLP-1 drugs. Joining us right now is CNBC contributor Dr. . Scott Gotautle.He is the former commissioner of the FDA and he serves on the boards of both Aluminina, Fizer, and United Health. He's also on the CNBC cures advisory board. And Scott, thank you for coming in today.>> Thanks a lot. >> Uh, break this down for us. hims and hers big splashy announcement last week that they were going to be ...

Wegovy and Ozempic maker Novo Nordisk filed a lawsuit against Hims & Hers as it seeks a ban on the telehealth provider offering copycat versions of its weight-loss and obesity medications https://t.co/4ebA8AHWRN ...

Core Viewpoint - Novo Nordisk's shares experienced a significant increase, climbing over 7% in Denmark and nearly 6% in US premarket trading following news related to telehealth company Hims & Hers [1] Group 1 - Novo Nordisk's stock performance indicates strong market confidence, reflecting positive investor sentiment [1] - The rise in share price may be linked to strategic developments or market reactions to Hims & Hers' business decisions [1]

Market Overview - Major U.S. index futures indicate a flat open on Monday, with stocks lacking direction after a significant advance on Friday [1] - Traders are assessing recent volatility, particularly a tech-led decline followed by a rebound [1] - A lack of major U.S. economic data may keep traders cautious ahead of key reports [1] Employment and Economic Data - The Labor Department's monthly jobs report is expected to show an increase of 70,000 jobs in January, up from 50,000 in December, with the unemployment rate holding at 4.4% [2] - Reports on retail sales and consumer price inflation are anticipated to influence interest rate outlooks [2] Stock Market Performance - Stocks rebounded significantly on Friday, with the Dow closing above 50,000 for the first time, gaining 1,206.95 points (2.5%) to 50,115.67 [3][4] - The Nasdaq surged 490.63 points (2.2%) to 23,031.21, and the S&P 500 jumped 133.90 points (2.0%) to 6,932.30 [4] - For the week, the Dow rose by 2.5%, while the S&P 500 edged down by 0.1% and the Nasdaq fell by 1.8% [4] Sector Performance - Bargain hunting contributed to the rally, particularly in tech stocks, which had previously dragged the Nasdaq down [5] - Airline stocks saw a significant increase, with the NYSE Arca Airline Index rising by 7.1% [8] - Computer hardware and semiconductor stocks rebounded sharply, with the NYSE Arca Computer Hardware Index up by 6.8% and the Philadelphia Semiconductor Index up by 5.7% [9] - Gold stocks also strengthened, reflected by a 5.5% increase in the NYSE Arca Gold Bugs Index due to rising gold prices [9] Consumer Sentiment - The University of Michigan reported an unexpected rise in consumer sentiment, with the index increasing to 57.3 in February from 56.4 in January, surpassing expectations [6][7] - The increase in sentiment was particularly notable among consumers with larger stock portfolios [7] International Markets - Asian stocks surged, recovering from previous declines, with Japan's Nikkei 225 Index closing up 3.9% [12][14] - Seoul stocks rose significantly, driven by confidence in the AI industry, with Samsung Electronics gaining 4.9% [15] - European stocks are broadly higher, with notable gains in the tech sector and merger activity [18][19]